Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31208581 | 1.00 | SSTR4 (0.33) | SSTR4 | |
| SCHEMBL34474875 | 1.00 | SSTR4 (0.33) | SSTR4 | |
| SCHEMBL31209640 | 0.86 | SSTR4 (0.31) | SSTR4 | |
| SCHEMBL31209282 | 0.84 | — | — | |
| SCHEMBL24792230 | 0.81 | SSTR4 (0.30) | SSTR4 | |
| SCHEMBL34473341 | 0.78 | — | — | |
| SCHEMBL18968286 | 0.76 | — | — | |
| SCHEMBL25692436 | 0.76 | — | — | |
| SCHEMBL785780 | 0.76 | — | — | |
| SCHEMBL24875323 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368193-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2024-11-07 | — | — | US | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | BRISTOL MYERS SQUIBB CO (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2023-06-01 | — | — | US | disclosed |
| US-20220402950-A1 | SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2022-12-22 | — | — | US | disclosed |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADLOCK THERAPEUTICS, INC. | 2017-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220402950-A1 | SUBSTITUTED BENZIMIDAZOLES AS PAD4 INHIBITORS | PADI4, PADI1, PADI6 | SSTR4 4015/4885 |
| US-20230203039-A1 | MACROCYCLIC PAD4 INHIBITORS USEFUL AS IMMUNOSUPPRESSANT | PADI4, PADI1, PADI2 | SSTR4 1467/4885 |
| US-11524959-B1 | Indole and azaindole inhibitors of pad enzymes | PADI4, PADI1, PADI2 | SSTR4 1760/4885 |
| US-20170166565-A1 | BICYCLIC INHIBITORS OF PAD4 | PADI4, PADI1, PADI2 | SSTR4 4142/4885 |
| US-20240368193-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | SSTR4 1293/4885 |
| US-20230167131-A1 | HETEROCYCLIC PAD4 INHIBITORS | PADI4, PADI2, PADI6 | SSTR4 2662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.